AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11834237 — intervention group
Group type: COMPARATOR
Intervention: Nonoxynol-9 (Conceptrol), active control
Number of subjects: 36
Study 9568181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistletoe lectin (ML-1) standardized therapy; subcutaneous administration of 0.5-1.0 ng ML-1/kg body weight, twice a week
Number of subjects: 0
Study 8309029 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) niacin at 1500 mg/d and above
Number of subjects: 46
Study 8309029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) niacin at 1500 mg/d and above
Number of subjects: 46
Study 8309029 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) niacin
Number of subjects: 46
Study 8309029 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release (SR) niacin
Number of subjects: 46
Study 8309029 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IR and SR niacin
Number of subjects: 46
Study 3058614 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroplasty
Number of subjects: 57
Study 3058614 — intervention group
Group type: COMPARATOR
Intervention: Very-Low-Calorie Diet (VLCD)
Number of subjects: 57
Study 17894065 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (lysergic acid diethylamide)
Number of subjects: 0
Study 17894065 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (dextroamphetamine)
Number of subjects: 0
Study 17894065 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD and DA
Number of subjects: 0
Study 29614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg/d
Number of subjects: 75
Study 29614865 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 75
Study 29614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsed ITP
Number of subjects: 75
Study 29614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone in relapsed subgroup
Number of subjects: 75
Study 29614865 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 75
Study 27629581 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Reduction Therapy for Adolescents (RRTA)
Number of subjects: 105
Study 27629581 — intervention group
Group type: COMPARATOR
Intervention: Usual Services (US)
Number of subjects: 105
Study 26702161 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg melatonin
Number of subjects: 76
Study 26702161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23134807 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Olympics Unified Sports soccer training program (8 weeks, 1.5 hours per session, three times per week)
Number of subjects: 46
Study 23134807 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (CG) without specific training
Number of subjects: 46
Study 20673994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for adolescents with mental health problems; details on dosage and duration not specified.
Number of subjects: 0
Study 20673994 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study 18325242 — intervention group
Group type: EXPERIMENTAL
Intervention: PriMa program (school-based prevention program for anorexia nervosa)
Number of subjects: 1006
Study 18325242 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires used in the evaluation
Number of subjects: 1006
Study 18325242 — intervention group
Group type: EXPERIMENTAL
Intervention: Program user feedback
Number of subjects: 1006
Study 16523251 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 416
Study 14503430 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous gastric feeding
Number of subjects: 45
Study 14503430 — intervention group
Group type: COMPARATOR
Intervention: Intermittent gastric feeding
Number of subjects: 45
Study 11885182 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated implants
Number of subjects: 2900
Study 11885182 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated implants
Number of subjects: 2900
Study 8703169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (5000 units, subcutaneously every 12 hours)
Number of subjects: 344
Study 8703169 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (enoxaparin, 30 mg, subcutaneously every 12 hours)
Number of subjects: 344
Study 8703169 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 344
Study 8703169 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 344
Study 8703169 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 344
Study 1411449 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 26
Study 1411449 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 26
Study 1411449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3890872 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 500 mg b.d. for 3 months
Number of subjects: 10
Study 3890872 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 10
Study 29746232 — intervention group
Group type: EXPERIMENTAL
Intervention: AboutFace (web-based video gallery)
Number of subjects: 60
Study 29746232 — intervention group
Group type: COMPARATOR
Intervention: Educational booklet about PTSD treatment
Number of subjects: 60
Study 30268456 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary nodules group (nodule group)
Number of subjects: 338
Study 30268456 — intervention group
Group type: COMPARATOR
Intervention: Normal CT group
Number of subjects: 338
Study 26842751 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit interviews conducted on days of consultations
Number of subjects: 19579
Study 24912463 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral treatment with motivational support
Number of subjects: 262
Study 24912463 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral treatment without motivational support
Number of subjects: 262
Study 21771277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rhPTH(1‐84) at 0.5‐5.0 μg/kg
Number of subjects: 32
Study 21771277 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of rhPTH(1‐84) at 1.0, 2.0, and 4.0 μg/kg
Number of subjects: 32
Study 21771277 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of rhPTH(1‐84) at 2.0 μg/kg once daily for 7 days
Number of subjects: 32
Study 21771277 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of rhPTH(1‐34) at 2.0 μg/kg once daily for 7 days
Number of subjects: 32
Study 21771277 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dosing at 4 hr
Number of subjects: 32
Study 20677916 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolieve System
Number of subjects: 34
Study 20677916 — intervention group
Group type: COMPARATOR
Intervention: Targis System
Number of subjects: 34
Study 17391172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tri-iodothyronine (T3)
Number of subjects: 0
Study 17391172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15604153 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 11444997 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapeutic ultrasound
Number of subjects: 35
Study 9133749 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 2 mg
Number of subjects: 81
Study 9133749 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 6 mg
Number of subjects: 81
Study 9133749 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine 225 mg
Number of subjects: 81
Study 9133749 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study 7962327 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 infusion (150 micrograms)
Number of subjects: 8
Study 7962327 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-6 administered sc for 42 consecutive days (150 micrograms)
Number of subjects: 8
Study 7962327 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study 3673933 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambian meal of rice with groundnut sauce
Number of subjects: 0
Study 3673933 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 0
Study 29304544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior preterm birth
Number of subjects: 653
Study 29304544 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior term birth
Number of subjects: 653
Study 25637070 — intervention group
Group type: EXPERIMENTAL
Intervention: Wish intervention (granting a wish)
Number of subjects: 0
Study 25637070 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 26289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex (9‐delta‐tetrahydrocannabinol plus cannabidiol) oromucosal spray for 4 weeks (including 2 weeks' titration)
Number of subjects: 34
Study 26289497 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks (including 2 weeks' titration)
Number of subjects: 34
Study 26289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex
Number of subjects: 34
Study 26289497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 26289497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sativex and Placebo
Number of subjects: 34
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG3-Ro60(K170A R174A)
Number of subjects: 0
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAG3-Ro60(H187S)
Number of subjects: 0
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: mY3 RNA interference in wild-type fibroblasts
Number of subjects: 0
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: mY1 RNA interference
Number of subjects: 0
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of mY1 in mY3-depleted fibroblasts
Number of subjects: 0
Study 23698747 — intervention group
Group type: EXPERIMENTAL
Intervention: Y RNA in an in vitro model of anti-Ro60-mediated injury
Number of subjects: 0
Study 19881358 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/d) added to UDCA
Number of subjects: 8
Study 18955671 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) positive patients
Number of subjects: 490
Study 18955671 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA) negative patients
Number of subjects: 490
Study 18955671 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA testing overall
Number of subjects: 490
Study 18955671 — intervention group
Group type: EXPERIMENTAL
Intervention: TWA-negative patients
Number of subjects: 490
Study 16640105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin-alpha1 (1.6 microg three times per week) and lymphoblastoid interferon (5 MIU three times per week)
Number of subjects: 98
Study 16640105 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with lymphoblastoid interferon (5 MIU three times per week)
Number of subjects: 98
Study 16640105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 98
Study 16640105 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy and monotherapy
Number of subjects: 98
Study 14674810 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned purpose goals
Number of subjects: 0
Study 14674810 — intervention group
Group type: EXPERIMENTAL
Intervention: Adopted purpose goals
Number of subjects: 0
Study 14674810 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent mastery-approach goals
Number of subjects: 0
Study 14674810 — intervention group
Group type: COMPARATOR
Intervention: Neutral purpose goal context (Control)
Number of subjects: 0
Study 14674810 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent purpose goals
Number of subjects: 0
Study 10905766 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0
Study 10905766 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy (HDT)
Number of subjects: 0
Study 10905766 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 9196087 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 250 microg twice daily for 6 weeks
Number of subjects: 20
Study 9196087 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 20
Study 9196087 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study 1567346 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal
Number of subjects: 6
Study 1567346 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 6
Study 1567346 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 6
Study 6423796 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (10.8 mg/kg/day)
Number of subjects: 20
Study 6423796 — intervention group
Group type: COMPARATOR
Intervention: Control group (without taurine supplementation)
Number of subjects: 20
Study 31102881 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online feedback on alcohol use risk severity
Number of subjects: 724
Study 31102881 — intervention group
Group type: COMPARATOR
Intervention: No-feedback condition
Number of subjects: 724
Study 29648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch sequences with invariant secondary dimension
Number of subjects: 0
Study 29648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration sequences with invariant secondary dimension
Number of subjects: 0
Study 29648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitch sequences with randomized secondary dimension
Number of subjects: 0
Study 29648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pitch and duration sequences
Number of subjects: 0
Study 27006514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 14
Study 27006514 — intervention group
Group type: COMPARATOR
Intervention: Non-sleep-deprived condition
Number of subjects: 14
Study 25819980 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health (WYHH) intervention; a 32-week community health promoter-facilitated walking group intervention, meeting three times per week for 45 to 90 minutes.
Number of subjects: 0
Study 25819980 — intervention group
Group type: COMPARATOR
Intervention: Lagged intervention (control) group; no specific intervention details provided.
Number of subjects: 0
Study 25819980 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk Your Heart to Health (WYHH) intervention; a 32-week community health promoter-facilitated walking group intervention.
Number of subjects: 0
Study 23183514 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 20
Study 23183514 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/day)
Number of subjects: 20
Study 23183514 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 20194413 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia care management program
Number of subjects: 92
Study 20194413 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 18543135 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM)
Number of subjects: 865
Study 18543135 — intervention group
Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142)
Number of subjects: 865
Study 18543135 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM) in sedated patients
Number of subjects: 865
Study 18543135 — intervention group
Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142) in sedated patients
Number of subjects: 865
Study 18543135 — intervention group
Group type: COMPARATOR
Intervention: Traditional mouthpiece (MB-142) in nonsedated patients
Number of subjects: 865
Study 18543135 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth-protecting mouthpiece (TPM) in nonsedated patients
Number of subjects: 865
Study 16329274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberries
Number of subjects: 0
Study 11860040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette abstinence for 31 days
Number of subjects: 96
Study 11860040 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued to smoke)
Number of subjects: 96
Study 10432174 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 8
Study 8562738 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic bacteriuria in women with diabetes mellitus
Number of subjects: 1072
Study 8562738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteriuric women
Number of subjects: 1072
Study 8562738 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboriginal women
Number of subjects: 1072
Study 8562738 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary leukocyte counts
Number of subjects: 1072
Study 8562738 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of diabetes and aboriginal origin
Number of subjects: 1072
Study 2139282 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant yeast-derived hepatitis B vaccine (YDV)
Number of subjects: 0
Study 2139282 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine (PDV)
Number of subjects: 0
Study 6343878 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim-sulfametrole (640 to 3200 mg)
Number of subjects: 95
Study 6343878 — intervention group
Group type: COMPARATOR
Intervention: Five-day trimethoprim-sulfametrole (160 to 800 mg twice daily)
Number of subjects: 95
Study 6343878 — intervention group
Group type: COMPARATOR
Intervention: Five-day trimethoprim (200 mg twice daily)
Number of subjects: 95
Study 31280772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 33
Study 31280772 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 33
Study 30249589 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting hospital admissions
Number of subjects: 135
Study 30249589 — intervention group
Group type: COMPARATOR
Intervention: Traditional symptom-counting algorithms
Number of subjects: 135
Study 30249589 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting corticosteroid need
Number of subjects: 135
Study 30249589 — intervention group
Group type: COMPARATOR
Intervention: Traditional algorithms
Number of subjects: 135
Study 26220570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit intake during weight loss
Number of subjects: 100
Study 26220570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake during weight loss
Number of subjects: 100
Study 26220570 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma carotenoid concentrations
Number of subjects: 100
Study 26220570 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intakes during weight loss
Number of subjects: 100
Study 24994074 — intervention group
Group type: EXPERIMENTAL
Intervention: CBG1
Number of subjects: 532
Study 24994074 — intervention group
Group type: EXPERIMENTAL
Intervention: CBG2
Number of subjects: 532
Study 22113223 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-bupivacaine (10 mg morphine and 0.5% bupivacaine)
Number of subjects: 60
Study 22113223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol-bupivacaine (100 mg tramadol and 0.5% bupivacaine)
Number of subjects: 60
Study 22113223 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study 20236904 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (Group 1)
Number of subjects: 40
Study 20236904 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus SE (Group 2)
Number of subjects: 40
Study 20236904 — intervention group
Group type: COMPARATOR
Intervention: Optibond Solo Plus (Group 5, Control)
Number of subjects: 40
Study 20236904 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian SPE (Group 4)
Number of subjects: 40
Study 20236904 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt SE (Group 3)
Number of subjects: 40
Study 17582567 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi vaccine
Number of subjects: 0
Study 17582567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-of-illness studies
Number of subjects: 0
Study 17582567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociobehavioral studies
Number of subjects: 0
Study 16762960 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose 30 mg
Number of subjects: 10
Study 16762960 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg (outflow dialyser line)
Number of subjects: 10
Study 16762960 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose 100 mg (inflow dialyser line)
Number of subjects: 10
Study 16762960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15153728 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral periprostatic lidocaine administration
Number of subjects: 0
Study 15153728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous synthetic opioid (meperidine or tramadol) administration
Number of subjects: 0
Study 15153728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile normal saline)
Number of subjects: 0
Study 11004138 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 46
Study 11004138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 46
Study 11004138 — intervention group
Group type: COMPARATOR
Intervention: Reteplase
Number of subjects: 46
Study 8623868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 180
Study 8623868 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 180
Study 1483371 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1%
Number of subjects: 164
Study 1483371 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 164